Skip to main content

Valneva to Partner with Instituto Butantan on Single-Shot Chikungunya Vaccine for Low- and Middle- Income Countries

Submitted by tjsavage on May 8, 2020 - 09:39 AM

Valneva SE, a specialty vaccine company, and Instituto Butantan, producer of immunobiologic products is preparing to start Phase 3 clinical studies of a single-shot chikungunya vaccine, VLA1553, in the United States later this year.

Content Source:

VALNEVA

Content Author:

VALNEVA

Tags: